Intuitive Surgical stock gains on analyst upgrades and $2.89 billion revenue

Intuitive Surgical (ISIN US46120E6023) is trading around $401 after a wave of analyst upgrades and a second-quarter report that showed $2.89 billion in revenue, up 18.4% year over year, and EPS of $2.80 versus the $2.48 consensus estimate.

Analysts turned more positive

MarketBeat said on August 13, 2026, that Oppenheimer lifted Intuitive Surgical to Outperform with a $500 target, while Bank of America Securities kept a Buy rating and set a $470 target; both calls frame the stock as a premium valuation story rather than a pure growth trade.

The same coverage points to a market cap near $141.75 billion and a closing price of $401.27 on August 12, 2026, which leaves the shares far below the 52-week high of $603.88 but still near the lower end of this year's trading band.

Second-quarter numbers still matter

The latest quarter also showed 468 da Vinci systems shipped, $1.73 billion in instrument and accessory sales, and $472 million in services revenue, a mix that highlights how recurring revenue remains central to the business.

That quarter compared with $2.44 billion of revenue and $658.4 million of net profit a year earlier, so the company added scale while maintaining strong profitability.

Da Vinci remains the core

The companys flagship da Vinci robotic surgery platform remains the main revenue engine, with recurring instruments, accessories, and services still doing much of the heavy lifting behind quarterly results.

Shares and valuation

Intuitive Surgical shares closed at $401.27 on August 12, 2026, with after-hours trading shown at $402.13 early on August 13, 2026. That leaves the stock at a market cap of about $151.39 billion and a price-to-earnings ratio near 45.99, according to the latest market quote pages.